title: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
abstract: Abundant deposition of bronchoalveolar fibrin and fibronectin occurs during the exudative phase of the adult respiratory distress syndrome (ARDS), promoting hyaline-membrane formation and subsequent alveolar fibrosis. To explore the mechanisms that account for the persistence of bronchoalveolar fibrin and fibronectin, we compared the activity of urokinase, which is necessary for plasminogen activation and fibrin degradation, in cell-free bronchoalveolar-lavage fluid from 8 patients with ARDS, 9 patients with acute pulmonary diseases other than ARDS, and 10 normal subjects. The mean level of urokinase activity in the lavage fluid from the patients with ARDS was 0.003 IU per milliliter of fluid (range, 0 to 0.008), which was significantly lower (P = 0.001) than the level in the fluid from either the patients with pulmonary diseases other than ARDS (0.118 IU per milliliter [range, 0.032 to 0.295]) or the normal subjects (0.129 IU per milliliter [range, 0.045 to 0.198]). The lavage fluid from all the patients with ARDS also had antiplasmin activity, which would promote the persistence of fibrin. A true decrease in urokinase activity was confirmed by the failure of the lavage fluid from the patients with ARDS to convert [125I]plasminogen to plasmin. Despite the low urokinase activity, immunochemical assays revealed normal levels of urokinase antigen in the fluid from the patients with ARDS, suggesting the presence of urokinase inhibitors. Inhibitors were demonstrated directly by a fibrin gel-underlay assay that detects complexes of urokinase with inhibitors. Plasminogen-activator inhibitor type 1 was the principal inhibitor identified. We conclude that increased antifibrinolytic activity due to both urokinase inhibitors and antiplasmins in the bronchoalveolar compartment of patients with ARDS contributes to the formation and persistence of hyaline membranes, a key component of alveolar histopathology in ARDS.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA.
authors.forename: P
authors.initials: P
authors.lastname: Bertozzi
authors.forename: B
authors.initials: B
authors.lastname: Astedt
authors.forename: L
authors.initials: L
authors.lastname: Zenzius
authors.forename: K
authors.initials: K
authors.lastname: Lynch
authors.forename: F
authors.initials: F
authors.lastname: LeMaire
authors.forename: W
authors.initials: W
authors.lastname: Zapol
authors.forename: H A
authors.initials: HA
authors.lastname: Chapman
mesh_terms: D000328:Adult; D000941:Antigens / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000201:enzymology*; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D008171:Lung Diseases / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D012128:Respiratory Distress Syndrome / Q000201:enzymology* / Q000209:etiology; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D000979:alpha-2-Antiplasmin / Q000378:metabolism
chemical_list: D000941:Antigens; D005353:Fibronectins; D000979:alpha-2-Antiplasmin; D005337:Fibrin; D014568:Urokinase-Type Plasminogen Activator